A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
The purpose of this study is to investigate the safety and efficacy for 52-week dosing of JR-131 in renal anemia patients with chronic kidney disease (CKD).
Inclusion Criteria: Patients being treated with erythropoiesis stimulating agent. Exclusion Criteria: Patients having complication or history of a cardiovascular / lung / brain infarction. Patients having a pronounced hemorrhagic lesion.